NASDAQ:BIOL BIOLASE (BIOL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About BIOLASE Stock (NASDAQ:BIOL) 30 days 90 days 365 days Advanced Chart Get BIOLASE alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.0010▼$0.012552-Week Range N/AVolumeN/AAverage Volume2.58 million shsMarket Capitalization$581 thousandP/E RatioN/ADividend YieldN/APrice Target$1.20Consensus RatingBuy Company Overview BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California. Read More BIOLASE Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreBIOL MarketRank™: BIOLASE scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBIOLASE has received no research coverage in the past 90 days.Read more about BIOLASE's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BIOL. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBIOLASE does not currently pay a dividend.Dividend GrowthBIOLASE does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BIOL. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for BIOL on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BIOLASE insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.27% of the stock of BIOLASE is held by insiders.Percentage Held by InstitutionsOnly 8.79% of the stock of BIOLASE is held by institutions.Read more about BIOLASE's insider trading history. Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOL Stock News HeadlinesBiolase Inc (BIOLQ)December 12, 2024 | finance.yahoo.comBiolase Inc. Faces Bankruptcy Amid Strategic Asset SaleNovember 21, 2024 | markets.businessinsider.com"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’s Masayoshi Son says it marks “the beginning of a golden age.” NVIDIA’s Jensen Huang insists it “will change everything.” Bill Gates even calls it “more profound than the PC.” While the mainstream is focused elsewhere, insiders like Kai-Fu Lee are saying this breakthrough could reshape the world faster than anything in history—and open a $24 trillion opportunity for early investors.August 18 at 2:00 AM | Behind the Markets (Ad)Sonendo, Inc. Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deJapan Dental Lasers Market Outlook to 2033, with Focus on Dental Surgical Lasers and Dental Welding LasersNovember 4, 2024 | finance.yahoo.comIncreasing Prevalence of Periodontal Diseases to Propel Dental Market Growth at a CAGR of 7.4% by 2031October 12, 2024 | theglobeandmail.comSonendo Executes Asset Purchase Agreement to Acquire Biolase AssetsOctober 9, 2024 | finance.yahoo.comBiolase stock in flux as company files for bankruptcyOctober 4, 2024 | investing.comSee More Headlines BIOL Stock Analysis - Frequently Asked Questions How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) issued its quarterly earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) EPS for the quarter, topping analysts' consensus estimates of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative trailing twelve-month return on equity of 1,782.73% and a negative net margin of 41.65%. When did BIOLASE's stock split? BIOLASE's stock reverse split on the morning of Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of BIOLASE? Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN). Company Calendar Last Earnings11/10/2021Today8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Dental equipment & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees160Year FoundedN/APrice Target and Rating Average Price Target for BIOLASE$1.20 High Price Target$2.00 Low Price Target$0.40 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($14.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.63 million Net Margins-41.65% Pretax Margin-41.56% Return on Equity-1,782.73% Return on Assets-55.31% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.36 Sales & Book Value Annual Sales$48.83 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / BookN/AMiscellaneous Outstanding Shares33,407,000Free Float33,317,000Market Cap$581 thousand OptionableNot Optionable Beta0.67 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BIOL) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.